Abstract: This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases.
Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
Type:
Grant
Filed:
May 17, 2004
Date of Patent:
June 14, 2011
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
Abstract: A therapeutic composition for the treatment, alleviation or prophylaxis of autoimmune conditions is described. The composition comprises an enzyme and an immunogen appropriate to the condition to be treated. The composition may be given in conventional fashion but is preferably given by intradermal injection.
Abstract: A new chewing gum comprising a gum member, with a central core or cavity, and a core element located within the central core or cavity. The chewing gum also comprises a dietary supplement, which may be incorporated in the central core, the cavity, or both. The core element can be of a range of consistencies, from fluid to gel-like. Optionally, the gum member may comprise crystals. Additionally, the crystals may comprise a dietary supplement. The chewing gum may be encapsulated with a coating. Multiple dietary supplements, of different or of the same varieties, may be incorporated into the chewing gum.
Abstract: Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and/or proteins.
Type:
Application
Filed:
December 28, 2010
Publication date:
May 26, 2011
Inventors:
Sathy V. Balu-Iyer, Robert M. Straubinger, Razvan Miclea, Aaron Peng
Abstract: The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability, including thermotolerance or thermostability, at increased or decreased pHs and temperatures.
Abstract: Contemplated compositions and methods are directed to the use of a proteinase to reduce capsaicin-induced pain sensation in a mammal. Preferably, the proteinase comprises a bromelain preparation in a liquid formulation for topical or enteral administration. In additional aspects of the inventive subject matter, a proteinase inhibitor is present in pepper spray to avoid inactivation of capsaicin by a proteinase.
Abstract: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.
Type:
Application
Filed:
April 27, 2009
Publication date:
May 12, 2011
Applicant:
DSM IP ASSETS B.V.
Inventors:
Cinderella Christina Gerhardt, Luppo Edens
Abstract: A method for the prevention and treatment of fungal infections and, therefore, consequent invasive mycosis in mammalian and avian species is described. The invention comprises a combination of ?-1,3(4)-endoglucanohydrolase, ?-1,3(4)glucan, diatomaceous earth, mineral clay, and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to inhibit enteric fungal colonization in the gut and consequent mycosis. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species.
Type:
Grant
Filed:
July 13, 2006
Date of Patent:
May 10, 2011
Assignee:
OmniGen Research, LLC
Inventors:
Steven Bruce Puntenney, Neil Elliott Forsberg
Abstract: The present invention relates to a cell-targeting complex comprising a targeting moiety and a deliverable compound, wherein said targeting moiety and said deliverable compound are joined by means of a (transition) metal ion complex having at least a first reactive moiety for forming a coordination bond with a reactive site of said targeting moiety and having at least a second reactive moiety for forming a coordination bond with a reactive site of said deliverable compound, and wherein said deliverable compound is a therapeutic compound.
Type:
Application
Filed:
July 20, 2006
Publication date:
May 5, 2011
Applicant:
KREATECH BIOTECHNOLOGY B.V.
Inventors:
Robert Jochem Heetebrij, Robbert Jan Kok, Eduard Gerhard Talman, Klaas Poelstra, Grietje Molema
Abstract: The present invention relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease-type-III and to compounds and compositions suitable for use in such a method.
Type:
Application
Filed:
July 8, 2009
Publication date:
May 5, 2011
Inventors:
Yuan-Tsong Chen, Priya Kishnani, Baodong Sun
Abstract: The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain.
Type:
Application
Filed:
May 10, 2007
Publication date:
May 5, 2011
Inventors:
Israel Vlodavsky, Neta Ilan, Flonia Levy-Adam, Ben-Zion Katz
Abstract: The present invention relates to methods for preventing, removing, reducing, or disrupting biofilm present on a surface, comprising contacting the surface with an alpha-amylase derived from a bacterium.
Type:
Application
Filed:
November 29, 2010
Publication date:
May 5, 2011
Applicants:
Novozymes A/S, Novozymes North America, Inc.
Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.
Type:
Grant
Filed:
November 17, 2006
Date of Patent:
May 3, 2011
Assignees:
Tokyo Metropolitan Organization for Medical Research, ALTIF Laboratories
Abstract: The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
Type:
Application
Filed:
October 5, 2010
Publication date:
April 21, 2011
Applicant:
AMICUS THERAPEUTICS, INC.
Inventors:
Robert Boyd, Gary Lee, Philip Rybczynski
Abstract: An I-CreI variant, wherein at least one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the human IL2RG gene. Use of said variant and derived products for the prevention and the treatment of X-linked severe combined immunodeficiency.
Abstract: The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K.
Abstract: The invention provides pre-mixture for animal feeding comprising: (a) a polymer or a mixture of polymers, with a content in mannose comprised between 10% and 100%; (b) ?-mannanase enzyme; and (c) an anti-binding agent; wherein the anti-binding agent has an absorptive capacity higher than 20%, and a bulk density which is comprised between 0.10 and 2.70 g/cm3. The pre-mixture of the invention diffuses better through the intestinal tract and effectively inhibits the colonization of Gram negative bacteria without affecting the growth of the animal.
Type:
Application
Filed:
April 7, 2009
Publication date:
April 14, 2011
Applicants:
INSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTÁRIES, INDUSTRIAL TÉCNICA PECUARIA, S.A.
Inventors:
Joaquim Brufau De Barberá, Ana Maria Pérez Vendrell, Ignasi Badiola Sanz, Silvia Peris Miras
Abstract: Provided is a method of attaching a molecule-of-interest to a microtube, by co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming a coat over an internal surface of the shell, the first polymeric solution is selected solidifying faster than the second polymeric solution and a solvent of the second polymeric solution is selected incapable of dissolving the first polymeric solution and wherein the second polymeric solution comprises the molecule-of-interest, thereby attaching the molecule-of-interest to the microtube. Also provided is an electrospun microtube comprising an electrospun shell, an electrospun coat over an internal surface of the shell and a molecule-of-interest attached to the microtube.
Type:
Application
Filed:
February 12, 2009
Publication date:
April 7, 2011
Applicant:
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
Inventors:
Eyal Zussman, Yael Dror, Jonathan Charles Kuhn
Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.
Type:
Application
Filed:
December 9, 2010
Publication date:
March 31, 2011
Applicant:
IMMUNOMEDICS, INC.
Inventors:
William J. McBride, Christopher A. D'Souza, Chien-Hsing Chang, David M. Goldenberg
Abstract: Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.
Type:
Grant
Filed:
December 14, 2006
Date of Patent:
March 29, 2011
Assignee:
Chemgen Corporation
Inventors:
David M. Anderson, Humg-Yu Hsiao, Lin Liu
Abstract: The present disclosure provides an effective method for the crystallization of proteins at high pressure. A preferential excluding agent, and optionally other reagents may be incorporated into the method. The method is applicable to substantially all proteins.
Type:
Application
Filed:
April 27, 2010
Publication date:
March 24, 2011
Inventors:
Matthew B. SEEFELDT, Theodore W. Randolph, Ryan Crisman
Abstract: The present invention relates, in general, to Pompe disease and, in particular, to a methods of treating Pompe disease and to compounds/constructs suitable for use in such methods.
Abstract: This invention relates to pesticide and antiparasitic compositions for the control of pests, diseases and parasites attacking plants and animals. The compositions include, at least one chitinolytic agent or a chitinolytic activity-inducing agent, and sulfide or a sulfide-producing agent from microorganisms or chemical compounds, wherein the chitinolytic agent or the chitinolytic activity-inducing agent and sulfur or a sulfur-producing agent obtaining from microorganisms or chemical compounds are concurrently applied at a range significantly lower than any of the above-mentioned compounds, when they are individually to attain effective control.
Type:
Application
Filed:
August 16, 2010
Publication date:
March 17, 2011
Applicant:
CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
Inventors:
Jesus Mena Campos, Eulogio Pimentel Vazquez, Armando Tomas Hernadez Garcia, Liuven Veloz Gonzalez, Marieta Marin Bruzos, Oscar Compte Alberto, Marilin Domingo Puente, Licette Leon Barreras, Merardo Pujol Ferrero, Juan Diego Mencho Ponce, Carlos Borroto Nordelo
Abstract: The present invention relates to an extruded rod-shaped device which comprises at least one biological substance and a lipoid composition that comprises a high melting lipid or lipoid component and a low melting lipid or lipoid component. The extruded rod-shaped device according to the present invention is obtainable by extrusion of a preparation comprising the lipoid composition and the at least one biological substance, the preparation being extruded at a temperature which is at or above the melting point of the low melting lipid or lipoid component but below the melting point of the high melting lipid or lipoid component. Such an extruded rod-shaped device is capable of continuously and homogenously releasing the biological substance into the body of an animal or a human while maintaining the biological activity the biological substance and may for example be used as an implant.
Abstract: Therapeutic compositions containing therapeutic agents and poly(beta-amino esters) or polymers thereof are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles and microparticles containing polymer/therapeutic agent complexes are also described.
Abstract: A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by Mycoplasma pneumoniae. In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down biofilm in the airway; and (2) a pharmaceutically acceptable carrier suitable for administration into the airway. The composition can further include ingredients such as a steroid, lysozyme, lactoferrin, or a peroxidase; if a peroxidase is included, the composition can further include an oxidase to generate peroxide as well as a substrate for the oxidase. The composition can be used in methods for treatment of an infection based on the ability of the composition to dissolve biofilm in the airway.
Abstract: A therapeutic composition and a method for rheumatoid arthritis is described. The composition comprises purified beta-glucuronidase at a concentration of between 200 and 10,000 Fishman units/ml and purified collagen at a concentration of between 0.5 and 2.5 mg/ml. The composition is administered by transdermal infusion or intradermal injection.
Abstract: Therapeutic compositions containing therapeutic agents and nitrogen-containing lipids are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles, microparticles, and complexes containing lipid/therapeutic agent complexes are also described.
Abstract: The invention provides an antimicrobial agent for use in the treatment of a Campylobacter species which has colonised the crop of a bird, wherein the bird is exposed to said antimicrobial agent one or more times and products for carrying out the same.
Type:
Application
Filed:
February 9, 2009
Publication date:
February 24, 2011
Applicant:
NOFIMA MAT AS
Inventors:
Knut Rudi, Magne Kaldhusdal, John Nordal
Abstract: This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods.
Type:
Application
Filed:
May 16, 2008
Publication date:
February 17, 2011
Inventors:
Michael Schlossmacher, Valerie Cullen, Lamya Shihabuddin, Seng H. Cheng
Abstract: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention.
Type:
Application
Filed:
October 18, 2010
Publication date:
February 10, 2011
Applicant:
BIOVA, L.L.C.
Inventors:
RONALD E. STROHBEHN, LISA R. ETZEL, JESSE FIGGINS
Abstract: A novel substance that has the physiological activity of the aglycone of isoflavones and the physiological activity of the culture of the basidiomycetes with the physiological activities being synergistically enhanced, obtained by cultivating a basidiomycetes having a ?-glucosidase activity in a medium containing an isoflavone, a method for producing it, and food, feedstuff and medicine containing it. The substance of the invention is improved in the physiological effect of the aglycone of isoflavones and the physiological effect of the culture of the basidiomycetes, and is not only useful as an anti-tumor agent but also is useful for therapy and/or prevention of osteoporosis and also as an immune enhancement agent.
Type:
Grant
Filed:
April 24, 2008
Date of Patent:
February 8, 2011
Assignee:
Amino Up Chemical Co., Ltd.
Inventors:
Ken-ichi Kosuna, Lan Yuan, Takehito Miura, Buxiang Sun
Abstract: Variants of Bacillus sp. no. 707 alpha amylase are provided that are produced more efficiently and thus more economically. Higher fermentation yields are achieved through introducing amino acid variations that promote solubility of the variant in a fermentation broth. Increased solubility allows more enzyme to remain in solution after expression in a host cell. This in turn increases the efficiency with which the expressed variant enzyme can be recovered from the fermentation broth.
Abstract: The present invention relates to an enzyme activity assay using rolling circle 5 amplification for verifying that a sample contains enzyme activity. The enzyme activity assayed is typically involved in processing of mismatched nucleotides and/or damaged nucleotides in a double stranded nucleic acid. The present invention relates to methods for determining the presence of enzyme activities involved in processing double stranded oligonucleotide. Methods are also directed against determining the presence 10 of nucleotide repair enzyme activities involved in the repair of a circular oligonucleotide. The present invention also relates to liquid compositions and solid support both comprising an oligonucleotide probe. Furthermore, the present invention relates to methods for testing the efficacy of a drug, for diagnosing, prognosing, treating a disease by determining the enzyme activity.
Type:
Application
Filed:
July 9, 2008
Publication date:
February 3, 2011
Inventors:
Jakob Schwalbe Lohmann, Magnus Stougaard, Jørn Erland Koch
Abstract: A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids.
Abstract: An antimicrobial composition and a method for administering the antimicrobial composition through the water or feed of livestock, wherein the antimicrobial composition is made up of lysozyme and various other agents that act synergistically with lysozyme, such as, dried egg powder, albumen, a sequestering agent and/or a lantibiotic. The composition is used to inhibit the growth of, and diseases and epidemiological significant effects caused by, Clostridium perfinigens, E, coli and Salmonella, in the gut of livestock. More particularly, the antimicrobial composition and method relate to a feed additive that can be administered to poultry and/or swine through their feed. The use of such a feed additive may also inhibit other enteric pathogens that may be present in the gut of livestock.
Type:
Application
Filed:
April 1, 2010
Publication date:
January 20, 2011
Applicant:
NEOVA TECHNOLOGIES, INC.
Inventors:
Stephen R. Smith, Stewart J. Ritchie, Guopeng Zhang
Abstract: A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.
Abstract: The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles.
Abstract: The present invention provides compositions comprising an antibiofilm enzyme, a soluble ?-N-acetylglucosaminidase similar to the dspB gene (DispersinB™), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using DispersinB™-based antimicrobial compositions.
Type:
Application
Filed:
October 12, 2007
Publication date:
January 13, 2011
Applicant:
Kane Biotech Inc.
Inventors:
Srinivasa Madhyastha, Nanda Yakandawala, Purushottam V. Gawande, Karen Lovetri, Jeffrey B. Kaplan, Daniel Rhoads, Lasha Gogokhia
Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
Type:
Application
Filed:
April 15, 2010
Publication date:
January 6, 2011
Inventors:
Douglas A. TRECO, Kenneth LOVEDAY, Marianne BOROWSKI
Abstract: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable ?-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.
Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.
Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) wherein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoid of sulfhydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.
Type:
Application
Filed:
March 12, 2010
Publication date:
December 30, 2010
Inventors:
LUDGER JOHANNES, DAVID GRIERSON, SYLVIE ROBINE, JEAN-CLAUDE FLORENT, PHILIPE MAILLARD, JACKY ROGER
Abstract: The present invention relates, generally, to compositions including lactoferrin, and to compositions including both lactoferrin and lysozyme. The present invention also includes topical formulations containing the compositions, methods of making the formulations, methods of using the formulations to treat various skin disorders/conditions, to treat wounds, and to methods of producing artificial skin using the composition, and methods of treating burns using the formulation, optionally in conjunction with the application of artificial skin.
Type:
Application
Filed:
February 21, 2007
Publication date:
December 30, 2010
Applicant:
VENTRIA BIOSCIENCE
Inventors:
Scott E. Deeter, Delia R. Bethell, Brandy Sargent
Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
Type:
Application
Filed:
June 23, 2010
Publication date:
December 30, 2010
Inventors:
Jean-Francois Rossignol, J. Edward Semple